

Intracellular Staining Permeabilization Wash Buffer (10X)

Catalog# / Size	421002 / 100 mL
Regulatory Status	RUO
Other Names	Perm/Wash, Permeabilization Buffer
Description	Intracellular Staining Permeabilization Wash Buffer is useful for intracellular staining procedures, e.g., in preparation of cells for staining intracellular cytokines or other proteins. Intracellular Staining Permeabilization Wash Buffer is used to permeabilize cells following fixation with Intracellular Staining Fixation Buffer (Cat. No. 420801). It is supplied as a 10X solution and should be diluted in deionized water prior to use. Intracellular Staining Permeabilization Wash Buffer has been formulated to have minimal effects on cells, reduce non-specific staining and enhance the signal to noise ratio. It can be used for antibody dilutions and cell washing during intracellular staining.

Product Details

Storage & Handling	The Intracellular Staining Perm wash buffer solution should be stored between 2°C and 8°C. Do not freeze.
Application	ICC. ICFC - Quality tested IHC - Reported in the literature, not verified in house
Recommended Usage	For use in permeabilization, dilute Intracellular Staining Permeabilization Wash Buffer (10X) to 1X in DI water. Resuspend fixed cells in diluted Intracellular Staining Permeabilization Wash Buffer and centrifuge at 350 xg for 5-10 minutes, and repeat the process twice. It is recommended that the reagent be titrated for optimal performance for each application. Please see " Intracellular Cytokine Staining Protocol " on BioLegend's website for more details.
Application Notes	The Intracellular Staining Permeabilization Wash Buffer (10X) may have crystallization or precipitation observed when it is stored at 2-8°C; however, this is normal and does not affect the buffer's performance. If there is heavy precipitation observed after dilution to 1X working solution, the buffer can be filtered to clarify the solution.
Application References	<ol style="list-style-type: none"> Smeltz RB. 2007. <i>J. Immunol.</i> 178:4786. Kang YJ, <i>et al.</i> 2007. <i>Nature Immunol.</i> 8:601. del Rio ML, <i>et al.</i> 2011. <i>Transplantation.</i> 92:1085. PubMed del Rio ML, <i>et al.</i> 2012. <i>J. Immunol.</i> 188:4885. PubMed Marongiu L, <i>et al.</i> 2013. <i>PLoS One.</i> 8:75684. PubMed Xiao Z, <i>et al.</i> 2013. <i>Mol Immunol.</i> 56:423. PubMed Kusner LL, <i>et al.</i> 2014. <i>PLoS One.</i> 9:102231. PubMed Ni PP, <i>et al.</i> 2014. <i>J Immunol.</i> 193:1778. PubMed
Product Citations	<ol style="list-style-type: none"> Li B, Schmidt N 2016. <i>PLoS One.</i> 11: 0162427. PubMed Darzaniazi M, <i>et al.</i> 2020. <i>Int J Mol Sci.</i> 21:00. PubMed Kim S, <i>et al.</i> 2020. <i>Development.</i> 147:00:00. PubMed Dumauthioz N, <i>et al.</i> 2020. <i>Cell Mol Immunol.</i> . PubMed Rappazzo CG, <i>et al.</i> 2020. <i>bioRxiv.</i> . PubMed Hanga MP, <i>et al.</i> 2021. <i>Biotechnol Bioeng.</i> 118:3175. PubMed Lentucci C, <i>et al.</i> 2017. <i>J Biol Chem.</i> 292:2754-2772. PubMed Glaser K, <i>et al.</i> 2015. <i>Immunol Lett.</i> 166: 19-27. PubMed Kusner L, <i>et al.</i> 2014. <i>PLoS One.</i> 9:102231. PubMed Khayrullina G, <i>et al.</i> 2020. <i>Skelet Muscle.</i> 10:16. PubMed Spitzer SO, <i>et al.</i> 2019. <i>Neuron.</i> 101:459. PubMed Li L, <i>et al.</i> 2017. <i>Sci Rep.</i> 10.1038/s41598-017-14000-z. PubMed Li Q, <i>et al.</i> 2022. <i>Cell Rep.</i> 40:111308. PubMed van Vloten JP, <i>et al.</i> 2022. <i>J Immunother Cancer.</i> 10:. PubMed Lebedeva IV, <i>et al.</i> 2021. <i>Cell Death Dis.</i> 12:770. PubMed Zhang L, <i>et al.</i> 2021. <i>J Immunol.</i> 207:590. PubMed Li X, <i>et al.</i> 2022. <i>Nat Commun.</i> 13:2794. PubMed Zhang Y, <i>et al.</i> 2020. <i>Oncol Lett.</i> 1.053472222. PubMed Stewart CA, <i>et al.</i> 2020. <i>bioRxiv.</i> . PubMed Huang X, <i>et al.</i> 2019. <i>Cancer Immunol Res.</i> 1.388888889. PubMed

21. Angiari S, *et al.* 2020. Cell Metab. 31:391. [PubMed](#)
22. Jacob A, *et al.* 2020. Nature Protocols. 14(12):3303-3332. [PubMed](#)
23. Stewart CA, *et al.* 2021. J Thorac Oncol. Online ahead of prin. [PubMed](#)
24. Kiritsy MC, *et al.* 2021. Elife. 10: [PubMed](#)
25. Poli V, *et al.* 2021. iScience. 24:103256. [PubMed](#)
26. Duan Q, *et al.* 2021. Front Cell Dev Biol. 9:761193. [PubMed](#)
27. Stegelmeier AA, *et al.* 2022. Biomedicines. 10: [PubMed](#)
28. Zhang S, *et al.* 2022. Cell Death Dis. 13:844. [PubMed](#)
29. Haque M, *et al.* 2021. STAR Protoc. 2:100264. [PubMed](#)
30. Martinez-Usatorre A, *et al.* 2020. Front Immunol. 11:340. [PubMed](#)
31. Martinez-Usatorre A, *et al.* 2019. Cancer Immunol Res. 0.995138889. [PubMed](#)
32. Goyal S, *et al.* 2017. Sci Rep. . 10.1038/s41598-017-18046-x. [PubMed](#)
33. Tsai CY, *et al.* 2022. J Biomed Sci. 29:47. [PubMed](#)
34. Gärtner F, *et al.* 2021. Front Immunol. 12:745132. [PubMed](#)
35. Gao F, *et al.* 2021. Front Cell Infect Microbiol. 10:593805. [PubMed](#)
36. Tang B, *et al.* 2020. Clin Cancer Res. 26:2216. [PubMed](#)
37. Jtte BB, *et al.* 2021. iScience. 24(8):102833. [PubMed](#)
38. Eslani M, *et al.* 2017. Invest Ophthalmol Vis Sci. 58(12):5507-5517. [PubMed](#)
39. Shinde MY, *et al.* 2017. J Biol Chem. 292:18240. [PubMed](#)
40. Haryadi L, *et al.* 2019. Vet World. 12:1529. [PubMed](#)
41. Ghose J, *et al.* 2018. Oncoimmunology. 7:e1486948. [PubMed](#)
42. Herda S, *et al.* 2021. Int J Cancer. 148:3097. [PubMed](#)
43. Lau H, *et al.* 2021. Int J Mol Sci. 22: [PubMed](#)
44. Zhou H, *et al.* 2022. J Clin Invest. 132: [PubMed](#)
45. Zhang X, *et al.* 2020. J Immunol. 205:1743. [PubMed](#)
46. Ni P, *et al.* 2014. J Immunol . 193:1778. [PubMed](#)
47. Sohrabi Y, *et al.* 2020. Front Immunol. 11:353. [PubMed](#)
48. Martinez-Usatorre A, *et al.* 2018. J Immunol. 201:792. [PubMed](#)
49. Subham S, *et al.* 2022. Breast Cancer Res Treat. Online ahead of print. [PubMed](#)
50. Lau H, *et al.* 2021. Xenotransplantation. 28:e12667. [PubMed](#)
51. Su W, *et al.* 2022. Front Immunol. 13:952338. [PubMed](#)
52. Ma Q, *et al.* 2022. Nat Commun. 13:4142. [PubMed](#)
53. Datta A, *et al.* 2022. J Fungi (Basel). 8: [PubMed](#)
54. Jiang P, *et al.* 2021. Nat Methods. 18:1181. [PubMed](#)
55. Zhan Y, *et al.* 2021. JCI Insight. 6: [PubMed](#)
56. Hendricks A, *et al.* 2021. Front Oncol. 11:646885. [PubMed](#)
57. Shamsi F, *et al.* 2021. Nat Metab. 3:485. [PubMed](#)
58. Xiao Z, *et al.* 2013. Mol Immunol. 56:423. [PubMed](#)
59. Hilpert C, *et al.* 2016. J Immunol. 197: 2780 - 2786. [PubMed](#)
60. Clancy-Thompson E, *et al.* 2018. Cancer Immunol Res. 1.308333333. [PubMed](#)
61. Cheng K, *et al.* 2021. Nat Commun. 12:2041. [PubMed](#)
62. Zhang X, *et al.* 2022. Theranostics. 12:1621. [PubMed](#)
63. Berical A, *et al.* 2022. Nat Commun. 13:4270. [PubMed](#)
64. Pearce V, *et al.* 2015. J Immunol. 195: 3206 - 3217. [PubMed](#)
65. Baek J, *et al.* 2017. Am J Pathol. 10.1016/j.ajpath.2017.02.011. [PubMed](#)
66. Zhang L, *et al.* 2021. Methods Mol Biol. 2388:175. [PubMed](#)
67. Rodriguez S, *et al.* 2020. Xenotransplantation. 27:e12554. [PubMed](#)
68. Chakraborty S, *et al.* 2022. Sci Transl Med. . [PubMed](#)
69. Leonard NA, *et al.* 2021. Cancers (Basel). 13: [PubMed](#)
70. Chen L, *et al.* 2021. Cell Death Differ. 28:1880. [PubMed](#)
71. Lownik JC, *et al.* 2019. J Immunol. 202:664. [PubMed](#)
72. Lau H, *et al.* 2020. Xenotransplantation. 27:e12555. [PubMed](#)
73. Mkhikian H, *et al.* 2022. Nat Aging. 2:231. [PubMed](#)
74. Li J, *et al.* 2022. J Tissue Eng. 13:20417314221127908. [PubMed](#)
75. Ouyang W, *et al.* 2021. Invest Ophthalmol Vis Sci. 62:25:00. [PubMed](#)
76. Nausch N, *et al.* 2017. PLoS Negl Trop Dis. 11(2):e0005415. [PubMed](#)
77. Xu Z, *et al.* 2016. Nat Commun. 7:10728. [PubMed](#)
78. Breznik JA, *et al.* 2018. Physiol Rep. 6:e13937. [PubMed](#)
79. Ren Y, *et al.* 2022. J Immunother Cancer. 10: [PubMed](#)
80. Wei W, *et al.* 2022. mSystems. 7:e0046922. [PubMed](#)
81. Zhao X, *et al.* 2022. Nat Protoc. 17:2240. [PubMed](#)
82. Yang J, *et al.* 2022. Microbiome. 10:149. [PubMed](#)
83. Alvandi Z, *et al.* 2022. J Am Heart Assoc. 11:e023695. [PubMed](#)
84. van Duijn A, *et al.* 2021. Cancer Immunol Immunother. Online ahead of print. [PubMed](#)
85. Jakic B, *et al.* 2021. Cell Death Dis. 12:187. [PubMed](#)
86. Li Q, *et al.* 2017. Front Immunol. 0.797916667. [PubMed](#)
87. Page N, *et al.* 2021. Nat Commun. 12:1009. [PubMed](#)
88. Gunasena M, *et al.* 2022. Sci Rep. 12:12377. [PubMed](#)
89. Liu X, *et al.* 2016. Sci Rep. 6:36722. [PubMed](#)
90. Rio M, *et al.* 2012. J Immunol. 188:4885. [PubMed](#)
91. Kundu K, *et al.* 2019. Cancer Immunol Res. 1.069444444. [PubMed](#)
92. Bajpai G, *et al.* 2018. Nat Med. 24:1234. [PubMed](#)
93. Janela B, *et al.* 2019. Immunity. 50:1069. [PubMed](#)
94. Wilmes A, *et al.* 2017. Toxicol In Vitro. 10.1016/j.tiv.2017.07.023. [PubMed](#)
95. Hayes D, *et al.* 2022. JCI Insight. 7: [PubMed](#)
96. Gong C, *et al.* 2021. Mol Cell. 81:4059. [PubMed](#)
97. Chen DL, *et al.* 2021. Mol Cancer. 20:166. [PubMed](#)
98. Kim S, *et al.* 2020. Development. . [PubMed](#)
99. Henrich IC, *et al.* 2021. Cancer Res. 81:2171. [PubMed](#)
100. Rio M, *et al.* 2011. Transplantation. 92:1085. [PubMed](#)

101. Chen YF, *et al.* 2019. J Biomed Sci. 26:85. [PubMed](#)
102. Hiza H, *et al.* 2021. Sci Rep. 11:13190. [PubMed](#)
103. Wen T, *et al.* 2022. Cancer Immunol Res. 10:162. [PubMed](#)
104. Ma K, *et al.* 2022. iScience. 25:104347. [PubMed](#)
105. Lau H, *et al.* 2020. Islets. 41:12. [PubMed](#)
106. Lau H, *et al.* 2020. PLoS One. 15:e0243506. [PubMed](#)
107. Wang G, *et al.* 2020. Nat Commun. 0.6111111111. [PubMed](#)
108. Dong M, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
109. Shemesh A, *et al.* 2022. J Exp Med. 219:. [PubMed](#)
110. Teh MR, *et al.* 2021. Front Immunol. 12:714613. [PubMed](#)
111. Haswell JR, *et al.* 2021. PLoS One. 16:e0252848. [PubMed](#)
112. Wang Y, *et al.* 2020. Virol Sin. 36:122. [PubMed](#)
113. Park SR, *et al.* 2020. Cell Rep. 32:108077. [PubMed](#)
114. Ansari M, *et al.* 2017. Cell Signal. 10.1016/j.cellsig.2017.04.014. [PubMed](#)
115. Ahmad S, *et al.* 2017. Prog Neuropsychopharmacol Biol Psychiatry. 10.1016/j.pnpbp.2017.06.034. [PubMed](#)
116. Xia Y, *et al.* 2018. Cell. 175:1059. [PubMed](#)
117. Chen RH, *et al.* 2021. Front Immunol. 11:594775. [PubMed](#)
118. Spiliopoulou P, *et al.* 2022. Mol Cancer Ther. . [PubMed](#)
119. Tintos-Hernandez JA, *et al.* 2021. Brain Commun. 3:fcab215. [PubMed](#)
120. Koutník J, *et al.* 2022. Cell Commun Signal. 20:54. [PubMed](#)
121. Zhao X, *et al.* 2022. iScience. 25:104690. [PubMed](#)
122. Cébulo-Vázquez A, *et al.* 2022. PLoS One. 17:e0264566. [PubMed](#)
123. Gao J, *et al.* 2022. Front Immunol. 13:955812. [PubMed](#)
124. Lei L, *et al.* 2021. Front Cell Dev Biol. 659744:9. [PubMed](#)
125. Frafjord A, *et al.* 2020. Scand J Immunol. e12889:92. [PubMed](#)
126. Lownik JC, *et al.* 2020. Biochem Biophys Rep. 24:100803. [PubMed](#)
127. Labi V, *et al.* 2019. Genes Dev. 33:1673. [PubMed](#)
128. Sun X, *et al.* 2017. Microbes Infect. 10.1016/j.micinf.2017.08.007. [PubMed](#)
129. Rhoades NS, *et al.* 2022. Cell Rep. 39:110725. [PubMed](#)
130. Reuschl AK, *et al.* 2022. Cell Rep. 39:110650. [PubMed](#)
131. Tatangelo V, *et al.* 2022. Front Oncol. 12:877495. [PubMed](#)
132. Huang T, *et al.* 2022. Nat Commun. 13:3489. [PubMed](#)
133. Deng Y, *et al.* 2021. Nat Commun. 12:7041. [PubMed](#)
134. DiMuzio JM, *et al.* 2021. Vaccine X. 8:100098. [PubMed](#)
135. Lee G, *et al.* 2021. Viruses. 13:. [PubMed](#)
136. Hernandez AA, *et al.* 2020. J Immunol. 205:2806. [PubMed](#)
137. Su Y, *et al.* 2020. Cell. 1479:183. [PubMed](#)
138. Wawrzyniak M, *et al.* 2021. Pharmacol Res Perspect. 9:e00837. [PubMed](#)
139. McGaw C, *et al.* 2022. Nat Commun. 13:2833. [PubMed](#)
140. Wagner AK, *et al.* 2022. iScience. 25:105137. [PubMed](#)
141. Zheng L, *et al.* 2020. Clin Cancer Res. 26:3694. [PubMed](#)
142. Witt G, *et al.* 2020. Cell Biol Toxicol. . [PubMed](#)
143. Marongiu L, *et al.* 2013. PLoS One. 8:75684. [PubMed](#)
144. Giadone RM, *et al.* 2018. Amyloid. 25:148. [PubMed](#)
145. Gebremeskel S, *et al.* 2017. Cancer Immunol Res. 0.9625. [PubMed](#)
146. Sun Y, *et al.* 2022. iScience. 25:104846. [PubMed](#)
147. van Loon K, *et al.* 2022. Cancers (Basel). 14:. [PubMed](#)
148. Wang X, *et al.* 2022. Elife. 11:. [PubMed](#)
149. Liu X, *et al.* 2021. Adv Sci (Weinh). 8:e2100233. [PubMed](#)
150. Heckler M, *et al.* 2021. Cancer Discov. Online ahead of prin. [PubMed](#)
151. Zhang Z, *et al.* 2021. Front Immunol. 12:699478. [PubMed](#)
152. Spiljar M, *et al.* 2021. Cell Metab. 33:2231. [PubMed](#)
153. Chen Y, *et al.* 2021. Braz J Med Biol Res. 54:e9570. [PubMed](#)
154. Xiao C, *et al.* 2021. STAR Protoc. 2:100789. [PubMed](#)
155. Chen S, *et al.* 2020. Cancer Immunol Res. 1064:8. [PubMed](#)
156. Assadi G, *et al.* 2016. PLoS One. 11:e0168276. [PubMed](#)
157. Ikebuchi R, *et al.* 2016. Sci Rep. 6:35002. [PubMed](#)
158. Lei F, *et al.* 2012. J Vis Exp. 63: 3986. [PubMed](#)
159. Guo Z, *et al.* 2022. Neurobiol Pain. 12:100096. [PubMed](#)
160. Luvanda MK, *et al.* 2021. J Fungi (Basel). 7:. [PubMed](#)

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 *Detection of Intracellular Cytokines by Flow Cytometry* (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, *et al.* 1991. *Immunol. Rev.* 119:65.
3. Sander B, *et al.* 1993. *J. Immunol. Meth.* 166:201.
4. Prussin C, *et al.* 1995. *J. Immunol. Meth.* 188:117.

Gene ID

NA

Related Protocols

[Surface and Intracellular Cytokine Staining for Flow Cytometry - Video](#)

[Intracellular Flow Cytometry Staining Protocol](#)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587